Drilldown: Medicines
Medicines > classes 
:
Empathogen or
Sedative-Hypnotic or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)
:
Empathogen or
Sedative-Hypnotic or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) Use the filters below to narrow your results.
generic:
brand:
None (25) ·
(none, never marketed) (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Nuplazid (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
THIP (1) ·
Versed (1) ·
Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Melatonin receptor agonist (2) ·
Monoamine releasing agent (3) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
None (45) ·
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1)
starting dose:
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 47 results in range #1 to #47.